Logo image of OKYO

OKYO PHARMA LTD (OKYO) Stock Overview

USA - NASDAQ:OKYO - GG00BMFG5F62 - Common Stock

2.13 USD
+0.03 (+1.43%)
Last: 9/17/2025, 8:00:02 PM
2.17 USD
+0.04 (+1.88%)
After Hours: 9/17/2025, 8:00:02 PM

OKYO Key Statistics, Chart & Performance

Key Statistics
52 Week High3.35
52 Week Low0.9
Market Cap46.37M
Shares21.77M
Float14.52M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-0.34
PEN/A
Fwd PEN/A
Earnings (Next)12-22 2025-12-22
IPO07-17 2018-07-17
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


OKYO short term performance overview.The bars show the price performance of OKYO in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 40

OKYO long term performance overview.The bars show the price performance of OKYO in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 20 40 60 80 100

The current stock price of OKYO is 2.13 USD. In the past month the price decreased by -6.99%. In the past year, price increased by 110.89%.

OKYO PHARMA LTD / OKYO Daily stock chart

OKYO Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 20.85 390.07B
AMGN AMGEN INC 12.6 147.89B
GILD GILEAD SCIENCES INC 14.5 139.29B
VRTX VERTEX PHARMACEUTICALS INC 22.85 99.26B
REGN REGENERON PHARMACEUTICALS 12.83 62.06B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 59.21B
ARGX ARGENX SE - ADR 79.22 44.94B
ONC BEONE MEDICINES LTD-ADR 5.79 39.49B
INSM INSMED INC N/A 30.60B
NTRA NATERA INC N/A 24.08B
BNTX BIONTECH SE-ADR N/A 23.59B
BIIB BIOGEN INC 9.05 21.24B

About OKYO

Company Profile

OKYO logo image OKYO Pharma Ltd. operates as a biopharmaceutical company, which engages in the development of therapeutics for inflammatory eye diseases and chronic pain. The firm is focused on the discovery and development of novel molecules to treat neuropathic corneal pain and dry eye disease. Its research program focuses on a novel G Protein-Coupled Receptor (GPCR). The Company’s lead candidate, urcosimod, is a non-steroidal anti-inflammatory and non-opioid analgesic. Urcosimod consists of a 10-mer C-terminal Chemerin sequence, a linker (PEG-8), and Palmitic acid. The company has completed a Phase II trial in patients with DED and NCP. The firm also plans to evaluate its potential in benefiting patients with ocular neuropathic pain, uveitis and allergic conjunctivitis. The company is also evaluating OK-201, a bovine adrenal medulla (BAM), lipidated-peptide preclinical analogue candidate that is in the developmental stage.

Company Info

OKYO PHARMA LTD

Floor 4, 14/15 Conduit St

London GB

Employees: 4

OKYO Company Website

OKYO Investor Relations

Phone: 442074952379

OKYO PHARMA LTD / OKYO FAQ

What is the stock price of OKYO PHARMA LTD today?

The current stock price of OKYO is 2.13 USD. The price increased by 1.43% in the last trading session.


What is the ticker symbol for OKYO PHARMA LTD stock?

The exchange symbol of OKYO PHARMA LTD is OKYO and it is listed on the Nasdaq exchange.


On which exchange is OKYO stock listed?

OKYO stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for OKYO PHARMA LTD stock?

8 analysts have analysed OKYO and the average price target is 10.2 USD. This implies a price increase of 378.87% is expected in the next year compared to the current price of 2.13. Check the OKYO PHARMA LTD stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is OKYO PHARMA LTD worth?

OKYO PHARMA LTD (OKYO) has a market capitalization of 46.37M USD. This makes OKYO a Nano Cap stock.


How many employees does OKYO PHARMA LTD have?

OKYO PHARMA LTD (OKYO) currently has 4 employees.


What are the support and resistance levels for OKYO PHARMA LTD (OKYO) stock?

OKYO PHARMA LTD (OKYO) has a support level at 2.12. Check the full technical report for a detailed analysis of OKYO support and resistance levels.


Should I buy OKYO PHARMA LTD (OKYO) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does OKYO PHARMA LTD (OKYO) stock pay dividends?

OKYO does not pay a dividend.


When does OKYO PHARMA LTD (OKYO) report earnings?

OKYO PHARMA LTD (OKYO) will report earnings on 2025-12-22.


What is the Price/Earnings (PE) ratio of OKYO PHARMA LTD (OKYO)?

OKYO PHARMA LTD (OKYO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.34).


What is the Short Interest ratio of OKYO PHARMA LTD (OKYO) stock?

The outstanding short interest for OKYO PHARMA LTD (OKYO) is 0.21% of its float. Check the ownership tab for more information on the OKYO short interest.


OKYO Technical Analysis

ChartMill assigns a technical rating of 3 / 10 to OKYO. When comparing the yearly performance of all stocks, OKYO is one of the better performing stocks in the market, outperforming 91.28% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

OKYO Financial Highlights

Over the last trailing twelve months OKYO reported a non-GAAP Earnings per Share(EPS) of -0.34. The EPS increased by 79.21% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -127.98%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%85.03%
Sales Q2Q%N/A
EPS 1Y (TTM)79.21%
Revenue 1Y (TTM)N/A

OKYO Forecast & Estimates

8 analysts have analysed OKYO and the average price target is 10.2 USD. This implies a price increase of 378.87% is expected in the next year compared to the current price of 2.13.


Analysts
Analysts82.5
Price Target10.2 (378.87%)
EPS Next Y0%
Revenue Next YearN/A

OKYO Ownership

Ownership
Inst Owners5.49%
Ins Owners33.31%
Short Float %0.21%
Short Ratio0.21